RT Journal Article
SR Electronic
T1 An accurate and rapid Real-time PCR approach for human Monkeypox virus diagnosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.23.22276033
DO 10.1101/2022.06.23.22276033
A1 Wawina-Bokalanga, Tony
A1 Sklenovska, Nikola
A1 Vanmechelen, Bert
A1 Bloemen, Mandy
A1 Vergote, Valentijn
A1 Laenen, Lies
A1 André, Emmanuel
A1 Van Ranst, Marc
A1 Muyembe-Tamfum, Jean-Jacques
A1 Maes, Piet
YR 2022
UL http://medrxiv.org/content/early/2022/06/23/2022.06.23.22276033.abstract
AB Background Human monkeypox (MPX) is an emerging zoonotic disease caused by monkeypox virus (MPXV), which is endemic to Western and Central Africa. Despite being identified in captive monkeys in 1958, and in humans from the Democratic Republic of Congo (DRC) in 1970, a MPXV diagnostic test is not routinely implemented in diagnostic laboratories. Currently, a multi-country outbreak of MPXV has been ongoing in several European and American countries since May 2022.Methods To develop this real-time PCR assay, five MPXV positive DNA samples were tested using MPXV-specific primers. The qPCR amplification was conducted on two different qPCR devices. We also tested samples, collected in May 2022, from pox-like lesions of MPXV-suspected patients in Belgium.Results The performance of our real-time PCR was proved with five MPXV positive DNA from DRC. In addition, five out of ten clinical samples, from the current MPXV-outbreak, tested positive with Ct values ranging from 20.6 to 34.9.Conclusions In this study, we present an accurate and rapid real-time PCR approach, based on conserved regions of both MPXV clades, that can be used to test clinical samples from MPXV-suspected persons. Our real-time qPCR assay can be used for the 2022 multi-country outbreak of human MPXV.Summary An accurate and fast real-time PCR assay is indispensable to diagnose cases of monkeypox during the 2022 multi-country outbreak.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for the work conducted at KU Leuven on the viral DNA samples was approved by the KU Leuven ethics committee under reference no. S58836.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors